This CryptoPunk NFT Just Sold For $109,415 in ETH

CryptoPunks are a generative art collection, and one of the first ever applications of NFTs for digital art. There are only 10,000 Punks in existence, and some of them are thought to be lost forever.

CryptoPunks are a generative art collection, and one of the first ever applications of NFTs for digital art. There are only 10,000 Punks in existence, and some of them are thought to be lost forever.

What happened: CryptoPunk #8370 just sold for 77.77 ETH (CRYPTO: ETH) ($109,415 USD). The value of CryptoPunks is typically determined by Punk’s attributes, with the hoodie, beanie, and pilot helmet traits being the most coveted. Other species of Punks (Zombies, Apes and Aliens) are incredibly rare and also sell for a premium.

Here are a list of its attributes and how many other Punks have the same trait:

  • Type: Male (6,039)
  • Accessory: Chinstrap (282)
  • Accessory: Regular Shades (527)
  • Accessory: 2 Attributes (3,279)

Why it Matters: Cryptopunks are the ultimate rookie card for NFT collectors. CryptoPunks have earned huge influence in 2021, with dozens of Celebrities proudly showing off their punk ownership on Twitter. Cryptopunk sales are a leading indicator for the rest of the NFT market, and go to show that some are willing to spend serious coin on blockchain based art.

Price Action: Ethereum is currently trading at $1,696.94, down 2.91% over the past 24 hours.

See Also: NFT Release Calendar and Best NFT Projects of 2021

Data provided by OpenSea.

Checkout the full cryptopunk collection

You can learn more about this NFT here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Domo, Marvell Technology, PagSeguro And Other Big Stocks Moving Lower In Friday’s Pre-Market Session

U.S. stock futures traded higher this morning on Friday. Here are some big stocks recording losses in today’s pre-market trading session. Domo, Inc. (NASDAQ: DOMO) shares tumbled 25.5% to $12.70 in pre-market trading after the company issued FY24 guidance below estimates.

DOCN

Read More

Anemia Advantage For GSK’s Blood Cancer Therapy Could Influence Market Share Despite Incyte’s Jakafi Comparison

Friday, the FDA approved GSK plc's (NYSE: GSK) Ojjaara (momelotinib) for intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythemia vera and post-essential thrombocythaemia), in 

BMY